X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (65710) 65710
Book Review (14569) 14569
Newspaper Article (5022) 5022
Publication (4582) 4582
Newsletter (4576) 4576
Book Chapter (600) 600
Book / eBook (405) 405
Magazine Article (299) 299
Trade Publication Article (244) 244
Conference Proceeding (189) 189
Transcript (131) 131
Web Resource (68) 68
Dissertation (67) 67
Reference (9) 9
Data Set (7) 7
Government Document (6) 6
Paper (5) 5
Presentation (4) 4
Report (2) 2
Poster (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (52867) 52867
humans (46615) 46615
male (28534) 28534
female (24112) 24112
liver (20363) 20363
middle aged (20343) 20343
gastroenterology & hepatology (18157) 18157
adult (16552) 16552
liver diseases (14953) 14953
liver cirrhosis (13553) 13553
aged (11808) 11808
animals (11679) 11679
hepatitis (10841) 10841
cirrhosis (9108) 9108
liver cancer (8610) 8610
health aspects (8108) 8108
treatment outcome (8087) 8087
care and treatment (7760) 7760
research (7297) 7297
risk factors (7290) 7290
transplantation (7026) 7026
hepatocellular carcinoma (6813) 6813
hepatitis c (6589) 6589
analysis (6454) 6454
liver transplantation (6325) 6325
liver - pathology (6261) 6261
hepatitis c virus (6088) 6088
fibrosis (6064) 6064
abridged index medicus (6002) 6002
surgery (5951) 5951
cancer (5948) 5948
antiviral agents - therapeutic use (5422) 5422
oncology (5279) 5279
drug therapy (5159) 5159
patients (5064) 5064
disease (5029) 5029
medical research (4962) 4962
interferon (4936) 4936
therapy (4869) 4869
prognosis (4866) 4866
rats (4761) 4761
retrospective studies (4705) 4705
liver cirrhosis - drug therapy (4663) 4663
hepatology (4655) 4655
pharmacology & pharmacy (4616) 4616
mice (4613) 4613
liver cirrhosis - complications (4591) 4591
gastroenterology and hepatology (4576) 4576
hepatocellular-carcinoma (4576) 4576
medicine & public health (4531) 4531
mortality (4509) 4509
infections (4211) 4211
liver - metabolism (4066) 4066
medicine, experimental (3955) 3955
infection (3929) 3929
hepatoma (3841) 3841
adolescent (3824) 3824
hepatitis b (3799) 3799
medicine (3686) 3686
diagnosis (3653) 3653
liver - drug effects (3600) 3600
liver neoplasms - pathology (3453) 3453
hepatitis c, chronic - drug therapy (3449) 3449
rodents (3439) 3439
gastroenterology (3437) 3437
time factors (3386) 3386
biopsy (3375) 3375
immunology (3330) 3330
expression (3319) 3319
infectious diseases (3226) 3226
development and progression (3217) 3217
inflammation (3203) 3203
studies (3187) 3187
drug therapy, combination (3178) 3178
proteins (3104) 3104
liver cirrhosis - pathology (3083) 3083
carcinoma, hepatocellular - pathology (3034) 3034
survival (3022) 3022
medicine, general & internal (3006) 3006
follow-up studies (2973) 2973
clinical trials (2907) 2907
liver fibrosis (2879) 2879
apoptosis (2871) 2871
oxidative stress (2869) 2869
research article (2831) 2831
fatty liver (2710) 2710
disease progression (2682) 2682
antiviral agents (2678) 2678
prospective studies (2678) 2678
metabolism (2650) 2650
gene expression (2641) 2641
prevalence (2629) 2629
young adult (2625) 2625
article (2609) 2609
recurrence (2598) 2598
digestive system diseases (2586) 2586
aged, 80 and over (2578) 2578
management (2550) 2550
liver neoplasms - drug therapy (2542) 2542
liver-disease (2536) 2536
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (254) 254
Collection Dvlpm't (Acquisitions) - Closed Orders (16) 16
Online Resources - Online (12) 12
Collection Dvlpm't (Acquisitions) - Vendor file (10) 10
St. Michael's Hospital - Stacks (6) 6
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (6) 6
Scarborough Hospital - General (5) 5
Humber River Regional Hospital - Church Stacks (3) 3
Credit Valley Hospital - Reference (2) 2
Credit Valley Hospital - Stacks (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
Scarborough Hospital - Birchmount (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (2) 2
UofT at Mississauga - Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Bridgepoint Health - Stacks (1) 1
Church Stacks (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Gerstein Science - Reference (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Humber River Regional Hospital - Pharmacy (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
Robarts - Stacks (1) 1
St. Michael's Hospital - Online (1) 1
Sunnybrook Health Sciences Centre - Holland Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
Toronto East General Hospital - Online (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Oversize (1) 1
UofT at Mississauga - Reference (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (73382) 73382
German (783) 783
French (619) 619
Chinese (476) 476
Spanish (371) 371
Russian (323) 323
Japanese (300) 300
Italian (288) 288
Korean (85) 85
Polish (85) 85
Hungarian (74) 74
Czech (41) 41
Danish (37) 37
Romanian (31) 31
Portuguese (30) 30
Croatian (25) 25
Dutch (25) 25
Swedish (16) 16
Bulgarian (15) 15
Turkish (15) 15
Serbian (13) 13
Ukrainian (13) 13
Norwegian (9) 9
Slovak (6) 6
Finnish (5) 5
Hebrew (5) 5
Icelandic (1) 1
Persian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1973 - 1982
In patients with HCV genotype 1 infection and cirrhosis, the rate of sustained virologic response was 92% with three new antiviral agents plus ribavirin for 12... 
SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | UNITED-STATES | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | TELAPREVIR | THERAPY | GENOTYPE 1 INFECTION | BOCEPREVIR | HCV INFECTION | EPIDEMIOLOGY | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Logistic Models | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Complications and side effects | Evaluation | Care and treatment | Usage | Hepatitis C | Liver cirrhosis | Ribavirin | Headache | Antiviral agents | Ritonavir | Body weight | Fatigue | Infections | Nausea | Proteinase inhibitors | RNA polymerase | Patients | Cirrhosis | Liver cancer | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Cirrosi hepàtica | Inhibidors enzimàtics | Enzyme inhibitors | Hepatic cirrhosis
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 59, Issue 3, pp. 434 - 441
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 27, pp. 2618 - 2628
Journal Article
Gastroenterology, ISSN 0016-5085, 2015, Volume 149, Issue 3, pp. 649 - 659
Background & Aims There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. Methods... 
Gastroenterology and Hepatology | Liver Transplantation | Decompensated Cirrhosis | Hepatitis C Virus Infection | Fibrosing Cholestatic Hepatitis | C INFECTION | TRANSPLANTATION PATIENTS | RECIPIENTS | INTERFERON | THERAPY | ADEFOVIR DIPIVOXIL | CIRRHOSIS | GENOTYPE 1 INFECTION | OUTCOMES | GASTROENTEROLOGY & HEPATOLOGY | United States | Humans | Middle Aged | Fluorenes - therapeutic use | Liver Cirrhosis - mortality | Hepacivirus - genetics | Male | Cholestasis, Intrahepatic - drug therapy | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - mortality | Time Factors | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Cholestasis, Intrahepatic - virology | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Disease Progression | Cholestasis, Intrahepatic - mortality | Hepacivirus - enzymology | Liver Cirrhosis - virology | Cholestasis, Intrahepatic - diagnosis | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Drug Combinations | Care and treatment | Liver diseases | Hepatitis C virus | Hepatitis C | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 4, pp. 397 - 404
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 1, pp. 132 - 142.e4
Background & Aims We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C... 
Gastroenterology and Hepatology | Triple Therapy | Chronic Hepatitis C | DAA | CUPIC | LONG-TERM | RISK-FACTORS | CHRONIC HEPATITIS-C | RIBAVIRIN | COMPENSATED CIRRHOSIS | NATURAL-HISTORY | PEGINTERFERON | SUSTAINED VIROLOGICAL RESPONSE | PLUS SOFOSBUVIR | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT FAILURE | Recombinant Proteins - therapeutic use | Multivariate Analysis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Liver Cirrhosis - epidemiology | Treatment Failure | Aged, 80 and over | Adult | Female | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Liver Cirrhosis - drug therapy | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Proline - therapeutic use | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | Proline - adverse effects | Aged | Cohort Studies | Care and treatment | Protease inhibitors | Proteases | Genetic aspects | Hepatitis C virus | Hepatitis C | Health aspects | Liver cirrhosis | Index Medicus | Abridged Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 7, pp. 1680 - 1690.e1
Background & Aims Nonselective β blockers (NSBBs) reduce portal pressure and the risk for variceal hemorrhage in patients with cirrhosis. However, development... 
Gastroenterology and Hepatology | Liver Fibrosis | β Blocker | Bacterial Infection | Mortality | Adrenergic Receptor | β Blocker | SURVIVAL | ACUTE KIDNEY INJURY | beta Blocker | PROPRANOLOL | INFECTIONS | REFRACTORY ASCITES | LIVER-DISEASE | THERAPY | DYSFUNCTION | GASTROENTEROLOGY & HEPATOLOGY | PORTAL-HYPERTENSION | Liver Transplantation | Hypertension, Portal - physiopathology | Humans | Middle Aged | Liver Cirrhosis - mortality | Peritonitis - complications | Male | Hepatorenal Syndrome - diagnosis | Peritonitis - diagnosis | Hepatorenal Syndrome - physiopathology | Hypertension, Portal - diagnosis | Hypertension, Portal - mortality | Austria | Peritonitis - microbiology | Hypertension, Portal - etiology | Time Factors | Adrenergic beta-Antagonists - adverse effects | Female | Retrospective Studies | Acute Kidney Injury - etiology | Length of Stay | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Liver Cirrhosis - complications | Hepatorenal Syndrome - etiology | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Chi-Square Distribution | Hepatorenal Syndrome - mortality | Peritonitis - mortality | Hypertension, Portal - drug therapy | Disease-Free Survival | Acute Kidney Injury - mortality | Peritonitis - physiopathology | Aged | Hemodynamics - drug effects | Liver Cirrhosis - physiopathology | Paracentesis | Index Medicus | Abridged Index Medicus
Journal Article